Electra Therapeutics tumbles 16% as Q3 revenue hits zero on wider loss

Electra Therapeutics (ETRA.US) tumbled more than 16% during regular trading to $7.64.

The company reported fiscal third-quarter revenue of $0, with its net loss widening to $23.9 million, or $3.47 per share. Research and development expenses totaled $17.3 million, while general and administrative expenses were $7.8 million.

Electra said it holds $402.5 million in cash and securities, which it expects will fund operations into 2029.

Based on public media reports. AI-generated; not investment advice.